Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Mazdutide

Stage Phase 3Stale

Sponsor Innovent Biologics (Suzhou) Co

Route oral and injection

Class GLP-1 RA

Mechanism Mazdutide(Dual GLP-1R/GCGR Agonist)

Sources

registry, as of 2024-11-12Stale

https://clinicaltrials.gov/study/NCT05607680

A Study of IBI362 in Participants With Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 610. Conditions Obesity Or Overweight. This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle i

ClinicalTrials.gov NCT05607680 protocol and results modules

registry, as of 2026-05-12Stale

https://clinicaltrials.gov/study/NCT06884293

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 479. Conditions Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD). This is a multicenter, randomized, open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 9 mg QW versus Semaglutide 2.4 mg QW in overweight or obese (BMI≥27kg/m2) MAFLD subjects. Subjects will be randomly assigned to IBI362 9 mg and Semaglutide 2.4 mg grou

ClinicalTrials.gov NCT06884293 protocol and results modules

registry, as of 2024-08-27Stale

https://clinicaltrials.gov/study/NCT06164873

A Study of IBI362 9 mg in Chinese Adults With Obesity. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 462. Conditions Obesity. This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-week

ClinicalTrials.gov NCT06164873 protocol and results modules

registry, as of 2026-06-11Stale

https://clinicaltrials.gov/study/NCT06184568

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 349. Conditions Type 2 Diabetes; Obesity. This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects. Subjects will be randomly assigned to IBI362 6 mg and Semalgutide 1 mg groups for 32 weeks

ClinicalTrials.gov NCT06184568 protocol and results modules

registry, as of 2026-05-27Stale

https://clinicaltrials.gov/study/NCT07469800

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 336. Conditions Overweight; Obesity; Hypertensive. A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment

ClinicalTrials.gov NCT07469800 protocol and results modules

registry, as of 2025-06-29Stale

https://clinicaltrials.gov/study/NCT06931028

A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2. Overall status RECRUITING. Phases PHASE3. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 260. Conditions Sleep Apnea; Obstructive; Obesity. This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of IBI362 in subjects with moderate-to-severe obstructive sleep apnea (OSA) and a body mass index (BMI) ≥28 kg/m2. Subjects will be randomly assigned t

ClinicalTrials.gov NCT06931028 protocol and results modules

registry, as of 2026-01-08Stale

https://clinicaltrials.gov/study/NCT07255209

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 180. Conditions Adolescents With Obesity or Overweight With Weight-Related Comorbidities. The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks o

ClinicalTrials.gov NCT07255209 protocol and results modules

registry, as of 2025-11-17Stale

https://clinicaltrials.gov/study/NCT04904913

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 328. Conditions Overweight/ Obesity. This is a multicenter, double-blind, randomized, placebo-controlled study conducted in overweight or obese subjects. This study is divided into the first stage and the second stage. The participant enrollment and data analysis in the two stage are independent and do not influence

ClinicalTrials.gov NCT04904913 protocol and results modules

registry, as of 2026-04-21Stale

https://clinicaltrials.gov/study/NCT06124807

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 179. Conditions Obesity; Overweight and Obesity. The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with Mazdutide compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks. Mean Percentage of Participants Who Achieve ≥5% Body Weight Reduction Week 32 Placebo 23.97 percentage of participants Baseline, Week 32, Week 48 Mean Percentage of Participants Who Achieve ≥5% Body Weight Reduction Week 32 3/6 mg Mazdutide 67.64 percentage of participants Baseline, Week 32, Week 48 Mean Percentage of Participants Who Achieve ≥5% Body Weight Reduction Week 32 10 mg Mazdutide

ClinicalTrials.gov NCT06124807 protocol and results modules

registry, as of 2026-09-22Stale

https://clinicaltrials.gov/study/NCT06862908

A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 141. Conditions Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Ejection Fraction. This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in Chinese subjects with heart failure with ejection fraction retention/mild ejection fraction reduction (HFpEF/HFmrEF) combined with obesity (BMI≥28kg

ClinicalTrials.gov NCT06862908 protocol and results modules

registry, as of 2026-08-24Stale

https://clinicaltrials.gov/study/NCT07781150

Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor Tongji Hospital. Enrollment 128. Conditions Obesity; Overweight; Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I; Endometrioid Endometrial Cancer. This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of mazdutide combined with a levonorgestrel-releasing intrauterine system (LNG-IUS) for fertility-sparing treatment in over

ClinicalTrials.gov NCT07781150 protocol and results modules

registry, as of 2025-12-15Stale

https://clinicaltrials.gov/study/NCT07000955

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 98. Conditions Obesity. This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study

ClinicalTrials.gov NCT07000955 protocol and results modules

registry, as of 2023-11-28Stale

https://clinicaltrials.gov/study/NCT04440345

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 60. Conditions Overweight or Obesity. This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Overweight or Obese Male and Female Subjects.

ClinicalTrials.gov NCT04440345 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07657676

Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity. Overall status RECRUITING. Phases PHASE4. Lead sponsor China National Center for Cardiovascular Diseases. Enrollment 116. Conditions Obesity & Overweight; Coronary Heart Disease. This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis a

ClinicalTrials.gov NCT07657676 protocol and results modules

registry, as of 2026-09-23Stale

https://clinicaltrials.gov/study/NCT07718126

Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME). Overall status RECRUITING. Phases PHASE4. Lead sponsor West China Hospital. Enrollment 60. Conditions Metabolic Dysfunction-Associated Steatohepatitis; Hepatic Steatosis; Living Liver Donors. The purpose of this study is to evaluate the efficacy and safety of a short-term (12-week) prehabilitation strategy combining mazdutide (a novel GLP-1/GCG receptor dual agonist) with lifestyle optimization, compared to lifestyle optimization alone, in potential living liver trans

ClinicalTrials.gov NCT07718126 protocol and results modules

registry, as of 2026-09-17Stale

https://clinicaltrials.gov/study/NCT07824895

Mazdutide for Weight Management and Gout in Adults With Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE4. Lead sponsor Hongwei Jiang. Enrollment 30. Conditions Gout; Obesity (BMI>30); Hyperuricemia; Metabolic Syndrome. This is a single-arm, open-label, pre-post controlled study to evaluate the effect of Mazdutide on the annualized flare rate (AFR) in adults with obesity and gout. The study will enroll 30 subjects aged 18 to 65 years with a Body Mass Index (BMI) ≥ 30.0 kg/m². Eligible participan

ClinicalTrials.gov NCT07824895 protocol and results modules

registry, as of 2023-11-14Stale

https://clinicaltrials.gov/study/NCT05815680

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 48. Conditions Overweight Subjects; Obese Subjects. This trial is conducted in China. The aim of the trial is to investigate the influence of IBI362 on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin, metformin, warfarin, atorvastatin,

ClinicalTrials.gov NCT05815680 protocol and results modules

registry, as of 2025-09-12Stale

https://clinicaltrials.gov/study/NCT06536023

This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 36. Conditions Adolescents With Obesity. The study is a first-in-pediatric assessment of the safety, tolerability, and pharmacokinetic characteristics of multiple doses of IBI362 in Chinese adolescent subjects with obesity. It employs a multicenter, randomized, double-blind, and placebo-controlled trial design. The stud

ClinicalTrials.gov NCT06536023 protocol and results modules

registry, as of 2021-07-08Stale

https://clinicaltrials.gov/study/NCT04773977

Clinical Study of IBI362 in Healthy Chinese Male Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 24. Conditions Overweight/Obesity. This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.

ClinicalTrials.gov NCT04773977 protocol and results modules

registry, as of 2026-10-27Stale

https://clinicaltrials.gov/study/NCT07897305

Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients. Overall status NOT_YET_RECRUITING. Phases NA. Lead sponsor Beijing Anzhen Hospital. Enrollment 700. Conditions Atrial Fibrillation (AF); Ablation Treatment; Obesity & Overweight; Mazdutide. This is a multicenter, open-label, superiority randomized controlled trial enrolling adult patients aged 18 to 75 years. All participants have abdominal obesity (BMI ≥ 28 kg/m² with specific waist circumference standards) and non-valvular atrial fibrillation, and have successfull

ClinicalTrials.gov NCT07897305 protocol and results modules

Studies

A Study of IBI362 in Participants With Obesity or Overweight

Registry NCT05607680

Phase Phase 3

Status Completed

Enrollment 610

Start 2022-11-14

Primary completion 2023-08-21

Study completion 2024-04-16

Placebo

Regimen once weekly

Weeks 4

Population Obesity Or Overweight

IBI362 4 mg

Dose 4 mg

Regimen once weekly

Weeks 4

Comparator placebo

Population Obesity Or Overweight

IBI362 6 mg

Dose 6 mg

Regimen once weekly

Weeks 4

Comparator placebo

Population Obesity Or Overweight

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

Registry NCT06884293

Phase Phase 3

Status Active, not recruiting

Enrollment 479

Start 2025-05-09

Primary completion 2026-12-31

Study completion 2027-06-30

Catalyst Primary completion. 2026-12-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide

Regimen once weekly

Weeks 4

Population Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

IBI362

Regimen once weekly

Weeks 4

Population Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

A Study of IBI362 9 mg in Chinese Adults With Obesity

Registry NCT06164873

Phase Phase 3

Enrollment 462

Start 2023-12-27

Primary completion 2025-06-27

Study completion 2025-09-19

Catalyst Primary completion. 2025-06-27. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo

Regimen once weekly

Population Obesity

IBI362

Regimen once weekly

Comparator placebo

Population Obesity

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

Registry NCT06184568

Phase Phase 3

Status Completed

Enrollment 349

Start 2024-02-29

Primary completion 2025-09-17

Study completion 2026-02-09

Catalyst Primary completion. 2025-09-17. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide

Regimen once weekly

Weeks 32

Population Type 2 Diabetes; Obesity

IBI362

Regimen once weekly

Weeks 32

Population Type 2 Diabetes; Obesity

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Registry NCT07469800

Phase Phase 3

Status Recruiting

Enrollment 336

Start 2026-04-23

Primary completion 2026-08-01

Study completion 2027-04-15

Catalyst Primary completion. 2026-08-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

IBI362 treatment Group

Regimen once weekly

Weeks 1

Comparator placebo

Population Overweight; Obesity; Hypertensive

Placebo Control Group

Regimen once weekly

Weeks 1

Population Overweight; Obesity; Hypertensive

A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

Registry NCT06931028

Phase Phase 3

Status Recruiting

Enrollment 260

Start 2025-06-12

Primary completion 2027-05-07

Study completion 2027-06-11

Catalyst Primary completion. 2027-05-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

placebo

Regimen once weekly

Weeks 4

Population Sleep Apnea; Obstructive; Obesity

IBI362

Regimen once weekly

Weeks 4

Comparator placebo

Population Sleep Apnea; Obstructive; Obesity

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

Registry NCT07255209

Phase Phase 3

Status Recruiting

Enrollment 180

Start 2025-12-29

Primary completion 2027-10-31

Study completion 2028-10-31

Catalyst Primary completion. 2027-10-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo

Population Adolescents With Obesity or Overweight With Weight-Related Comorbidities

IBI362-dose2

Comparator placebo

Population Adolescents With Obesity or Overweight With Weight-Related Comorbidities

IBI362-dose1

Comparator placebo

Population Adolescents With Obesity or Overweight With Weight-Related Comorbidities

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Registry NCT04904913

Phase Phase 2

Status Completed

Enrollment 328

Start 2021-06-08

Primary completion 2023-03-29

Study completion 2023-12-06

IBI362 high dose

Regimen once weekly

Weeks 24

Comparator placebo

Population Overweight/ Obesity

IBI362 low dose

Regimen once weekly

Weeks 24

Comparator placebo

Population Overweight/ Obesity

placebo

Regimen once weekly

Weeks 24

Population Overweight/ Obesity

IBI362 moderate dose

Regimen once weekly

Weeks 24

Comparator placebo

Population Overweight/ Obesity

IBI362 extra high dose

Regimen once weekly

Weeks 24

Comparator placebo

Population Overweight/ Obesity

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Registry NCT06124807

Phase Phase 2

Status Completed

Enrollment 179

Start 2023-11-17

Primary completion 2025-01-22

Study completion 2025-07-09

Catalyst Primary completion. 2025-01-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

3/6 Milligrams (mg) Mazdutide

Regimen once weekly

Comparator placebo

Population Obesity; Overweight and Obesity

deaths

participants with diarrhoea, 9 participantsStale

participants with nausea, 14 participantsStale

participants with vomiting, 7 participantsStale

10 mg Mazdutide

Dose 10 mg

Regimen once weekly

Weeks 32

Comparator placebo

Population Obesity; Overweight and Obesity

percent change in body weight, 96.1 %, week 32Stale

deaths

participants with diarrhoea, 12 participantsStale

participants with nausea, 22 participantsStale

participants with vomiting, 6 participantsStale

16 mg Mazdutide

Dose 16 mg

Regimen once weekly

Weeks 32

Comparator placebo

Population Obesity; Overweight and Obesity

percent change in body weight, 92.23 %, week 32Stale

deaths

participants with diarrhoea, 13 participantsStale

participants with nausea, 34 participantsStale

participants with vomiting, 24 participantsStale

Placebo

Regimen once weekly

Weeks 32

Population Obesity; Overweight and Obesity

percent change in body weight, 23.97 %, week 32Stale

deaths

participants with diarrhoea, 6 participantsStale

participants with nausea, 12 participantsStale

participants with vomiting, 1 participantsStale

3/6 mg Mazdutide

Dose 6 mg

Regimen once weekly

Weeks 32

Population Obesity; Overweight and Obesity

percent change in body weight, 67.64 %, week 32Stale

A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

Registry NCT06862908

Phase Phase 2

Status Active, not recruiting

Enrollment 141

Start 2025-03-26

Primary completion 2026-09-24

Study completion 2027-02-11

Catalyst Primary completion. 2026-09-24. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

IBI362 4.0mg

Dose 4.0mg

Regimen once weekly

Comparator placebo

Population Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Ejection Fraction

placebo

Regimen once weekly

Population Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Ejection Fraction

IBI362 6.0mg

Dose 6.0mg

Regimen once weekly

Comparator placebo

Population Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Ejection Fraction

MELIA

Registry NCT07781150

Phase Phase 2

Status Not yet recruiting

Enrollment 128

Start 2026-11-01

Primary completion 2029-06-30

Study completion 2031-06-30

Catalyst Primary completion. 2029-06-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

LNG-IUS plus Mazdutide

Regimen once weekly

Weeks 1

Comparator placebo

Population Obesity; Overweight; Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I; Endometrioid Endometrial Cancer

LNG-IUS plus Placebo

Regimen once weekly

Weeks 1

Population Obesity; Overweight; Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I; Endometrioid Endometrial Cancer

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

Registry NCT07000955

Phase Phase 1/2

Status Active, not recruiting

Enrollment 98

Start 2025-06-17

Primary completion 2026-09-30

Study completion 2027-05-14

Catalyst Primary completion. 2026-09-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

IBI362

Regimen once weekly

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Population Obesity

Tirzepatide

Regimen once weekly

Comparator placebo

Population Obesity

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Registry NCT04440345

Phase Phase 1/2

Status Completed

Enrollment 60

Start 2020-06-16

Primary completion 2021-06-16

Study completion 2021-08-06

IBI362

Comparator placebo

Population Overweight or Obesity

placebo

Population Overweight or Obesity

Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity

Registry NCT07657676

Phase Phase 4

Status Recruiting

Enrollment 116

Start 2026-09-14

Primary completion 2027-12-31

Study completion 2027-12-31

Catalyst Primary completion. 2027-12-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Experimental: Mazdutide

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity & Overweight; Coronary Heart Disease

Placebo

Regimen once weekly

Weeks 52

Population Obesity & Overweight; Coronary Heart Disease

PRIME

Registry NCT07718126

Phase Phase 4

Status Recruiting

Enrollment 60

Start 2026-09-01

Primary completion 2029-02-28

Study completion 2029-08-31

Catalyst Primary completion. 2029-02-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

GLP-1/GCG receptor dual agonist plus lifestyle optimization (GG Group)

Regimen once weekly

Weeks 1

Comparator placebo

Population Metabolic Dysfunction-Associated Steatohepatitis; Hepatic Steatosis; Living Liver Donors

Lifestyle optimization only (LL group)

Regimen once weekly

Weeks 1

Population Metabolic Dysfunction-Associated Steatohepatitis; Hepatic Steatosis; Living Liver Donors

Mazdutide for Weight Management and Gout in Adults With Obesity

Registry NCT07824895

Phase Phase 4

Status Not yet recruiting

Enrollment 30

Start 2026-09-15

Primary completion 2027-12-31

Study completion 2028-03-31

Catalyst Primary completion. 2027-12-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Mazdutide Treatment Group

Regimen once weekly

Weeks 4

Population Gout; Obesity (BMI>30); Hyperuricemia; Metabolic Syndrome

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Registry NCT05815680

Phase Phase 1

Status Completed

Enrollment 48

Start 2023-04-06

Primary completion 2023-08-18

Study completion 2023-10-30

warfarin+atorvastatin+IBI362

Population Overweight Subjects; Obese Subjects

metformin+digoxin+IBI362

Population Overweight Subjects; Obese Subjects

This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity

Registry NCT06536023

Phase Phase 1

Status Completed

Enrollment 36

Start 2024-08-30

Primary completion 2025-07-22

Study completion 2025-08-01

Catalyst Primary completion. 2025-07-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

362-dose1-4mg

Dose 4mg

Regimen once weekly

Weeks 12

Comparator placebo

Population Adolescents With Obesity

362-dose2-6mg

Dose 6mg

Regimen once weekly

Weeks 12

Comparator placebo

Population Adolescents With Obesity

362-dose3-Placebo

Regimen once weekly

Weeks 12

Population Adolescents With Obesity

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Registry NCT04773977

Phase Phase 1

Status Completed

Enrollment 24

Start 2021-03-03

Primary completion 2021-03-09

Study completion 2021-06-17

IBI362 liquid formulation

Population Overweight/Obesity

IBI362 lyophilized powder

Population Overweight/Obesity

MOTIVE-AF

Registry NCT07897305

Phase Not applicable

Status Not yet recruiting

Enrollment 700

Start 2026-10-25

Primary completion 2028-12-30

Study completion 2028-12-30

Catalyst Primary completion. 2028-12-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Intervention Group

Regimen once weekly

Weeks 4

Population Atrial Fibrillation (AF); Ablation Treatment; Obesity & Overweight; Mazdutide

Control Group

Regimen once weekly

Weeks 4

Population Atrial Fibrillation (AF); Ablation Treatment; Obesity & Overweight; Mazdutide